<DOC>
	<DOCNO>NCT01037517</DOCNO>
	<brief_summary>Poor mobilization hematopoietic progenitor need support autologous transplantation serious clinical problem . We investigate role plerixafor administer risk population augment successful stem cell collection . OBJECTIVES To determine plerixafor administer day prior plan autologous collection first mobilization attempt peripheral blood CD34 ≤ 10X106/L : - increase number patient successfully collect one day - increase number patient successfully mobilize first collection attempt - cost neutral within Canadian set</brief_summary>
	<brief_title>Trial Augmented Mobilization Strategy With Plerixafor ( Mozobil® ) Population Risk Poor Stem Cell Mobilization</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>1 . Participants must 18 year age old 2 . Patients must able provide write consent 3 . Participants must diagnosis lymphoma multiple myeloma undergo autologous stem cell mobilization purpose ASCT 4 . Females child bear age ask use approve form contraception 1 . Patients pregnant breastfeed 2 . Patients whose creatinine ≥ 250 μM 3 . Serum AST , ALT total bilirubin &gt; 5X upper limit normal 4 . Acute infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma Lymphoma Patients undergo</keyword>
	<keyword>mobilization purpose autologous stem cell collection</keyword>
</DOC>